全文获取类型
收费全文 | 32586篇 |
免费 | 2466篇 |
国内免费 | 937篇 |
专业分类
耳鼻咽喉 | 657篇 |
儿科学 | 1430篇 |
妇产科学 | 170篇 |
基础医学 | 1696篇 |
口腔科学 | 667篇 |
临床医学 | 3289篇 |
内科学 | 4079篇 |
皮肤病学 | 517篇 |
神经病学 | 966篇 |
特种医学 | 1321篇 |
外科学 | 8644篇 |
综合类 | 3601篇 |
现状与发展 | 1篇 |
预防医学 | 1592篇 |
眼科学 | 187篇 |
药学 | 4882篇 |
20篇 | |
中国医学 | 931篇 |
肿瘤学 | 1339篇 |
出版年
2024年 | 25篇 |
2023年 | 622篇 |
2022年 | 958篇 |
2021年 | 1325篇 |
2020年 | 2248篇 |
2019年 | 1629篇 |
2018年 | 1553篇 |
2017年 | 1412篇 |
2016年 | 1271篇 |
2015年 | 1422篇 |
2014年 | 2334篇 |
2013年 | 3118篇 |
2012年 | 1845篇 |
2011年 | 1861篇 |
2010年 | 1522篇 |
2009年 | 1475篇 |
2008年 | 1414篇 |
2007年 | 1376篇 |
2006年 | 1077篇 |
2005年 | 1050篇 |
2004年 | 833篇 |
2003年 | 709篇 |
2002年 | 629篇 |
2001年 | 505篇 |
2000年 | 471篇 |
1999年 | 328篇 |
1998年 | 289篇 |
1997年 | 304篇 |
1996年 | 180篇 |
1995年 | 220篇 |
1994年 | 175篇 |
1993年 | 178篇 |
1992年 | 149篇 |
1991年 | 148篇 |
1990年 | 113篇 |
1989年 | 106篇 |
1988年 | 106篇 |
1987年 | 123篇 |
1986年 | 95篇 |
1985年 | 95篇 |
1984年 | 103篇 |
1983年 | 96篇 |
1982年 | 92篇 |
1981年 | 69篇 |
1980年 | 56篇 |
1979年 | 55篇 |
1978年 | 56篇 |
1977年 | 43篇 |
1976年 | 46篇 |
1975年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
S. Liu A. E. Patanwala J. M. Naylor N. Levy R. Knaggs J. A. Stevens B. Bugeja D. Begley K. E. Khor E. Lau R. Allen S. Adie J. Penm 《Anaesthesia》2023,78(10):1237-1248
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty. 相似文献
2.
3.
4.
《Revista de gastroenterologia de Mexico》2022,87(1):52-58
IntroductionThe sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking.MethodsA retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to assess hepatitis C treatment with the SOF/VEL combination (n = 231) and the sofosbuvir/velpatasvir/ribavirin (SOF/VEL/RBV) combination (n = 10). The primary efficacy endpoint was the percentage of patients that achieved SVR at 12 weeks after the end of treatment.ResultsOverall SVR was 98.8% (95% CI 97.35-100%). Only three patients did not achieve SVR, two of whom had cirrhosis and a history of previous treatment with peg-IFN. Of the subgroups analyzed, all the patients with HIV coinfection, three patients with genotype 3, and the patients treated with the SOF/VEL/RBV combination achieved SVR. The subgroups with the lower success rates were patients that were treatment-experienced (96.8%) and patients with F1 fibrosis (95.5%). The most frequent adverse events were fatigue, headache, and insomnia. No serious adverse events were reported.ConclusionTreatments with SOF/VEL and SOF/VEL/RBV were highly safe and effective, results coinciding with those of other international real-world studies. 相似文献
5.
Oxidative stress and inflammation are two possible mechanisms related to nephrotoxicity caused by environmental pollutants. Ellagic acid, a powerful antioxidant phytochemical, may have great relevance in mitigating pollutant-induced nephrotoxicity and preventing the progression of kidney disease. This review discusses the latest findings on the protective effects of ellagic acid, its metabolic derivatives, the urolithins, against kidney toxicity caused by heavy metals, pesticides, mycotoxins, and organic air pollutants. We describe the chelating, antioxidant, anti-inflammatory, antifibrotic, antiautophagic, and antiapoptotic properties of ellagic acid to attenuate nephrotoxicity. Furthermore, we present the molecular targets and signaling pathways that are regulated by these antioxidants, and suggest some others that should be explored. Nevertheless, the number of reports is still limited to establish the efficacy of ellagic acid against kidney damage induced by environmental pollutants. Therefore, additional preclinical studies on this topic are required, as well as the development of well-designed clinical trials. 相似文献
6.
7.
目的 建立纤溶酶反相高效液相色谱纯度测定方法。方法 采用SHISEIDO CAPCELL PAK C18 SG300(250 mm×4.6 mm,5 μm),以0.1%三氟乙酸溶液-乙腈(95:5)为流动相A,以0.08%三氟乙酸溶液-乙腈(20:80)为流动相B,进行梯度洗脱,体积流量为0.7 mL·min-1,检测波长280 nm,柱温40℃。参照2020年版《中国药典》四部9101药品质量标准分析方法验证指导原则进行专属性、检测限、耐用性考察。应用所建立的方法和分子排阻色谱法对3批样品纯度进行检测。结果 建立的反相色谱法专属性强,检测限为0.01%,耐用性强。对3批样品进行检测,质量分数在93.5%~96.9%,结果准确。结论 建立反相色谱法测定纤溶酶纯度,分辨率更高、重现性更好,可进行更好的质量控制。 相似文献
8.
9.
10.
IntroductionHip displacement is common in cerebral palsy (CP) and is related to the severity of neurological and functional impairment. It is a silent, but progressive disease, and can result in significant morbidity and decreased quality of life, if left untreated. The pathophysiology of hip displacement in CP is a combination of hip flexor-adductor muscle spasticity, abductor muscle weakness, and delayed weight-bearing, resulting in proximal femoral deformities and progressive acetabular dysplasia. Due to a lack of symptoms in the early stages of hip displacement, the diagnosis is easily missed. Awareness of this condition and regular surveillance by clinical examination and serial radiographs of the hips are the key to early diagnosis and treatment.Hip surveillance programmesSeveral population-based studies from around the world have demonstrated that universal hip surveillance in children with CP allows early detection of hip displacement and appropriate early intervention, with a resultant decrease in painful dislocations. Global hip surveillance models are based upon the patients’ age, functional level determined by the Gross Motor Function Classification system (GMFCS), gait classification, standardized clinical exam, and radiographic indices such as the migration percentage (MP), as critical indicators of progressive hip displacement.ConclusionDespite 25 years of evidence showing the efficacy of established hip surveillance programmes, there is poor awareness among healthcare professionals in India about the importance of regular hip surveillance in children with CP. There is a need for professional organizations to develop evidence-based guidelines for hip surveillance which are relevant to the Indian context. 相似文献